Additional Study to Commence at The David Geffen School of Medicine at the University of California Los Angeles (UCLA)
IRVINE, Calif., Oct. 9, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque announced today that the Company is supporting an additional preclinical study to expand the uses of compounds under the company's pending patents. The study is being conducted at UCLA's The David Geffen School of Medicine on a contract basis.
"We are pleased to commence this significant study," stated Thomas W. Gardner, CEO of AtheroNova. "This is a significant achievement for the Company as we work towards our goal of developing innovative new treatments for lipid related diseases."
AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development-stage biotechnology company targeting novel compounds to dissolve or regress atherosclerotic plaque deposits—a thickening of the arteries due to buildup of fat, cholesterol, and other substances. These plaque deposits, which progressively narrow and block the arteries, are the main underlying cause of cardiovascular disease, including heart attack, stroke, and peripheral artery disease (PAD). The Company's most advanced candidate, AHRO-001, works to significantly reduce the incidence and severity of plaque by employing a bile salt to dissolve existing atherosclerotic plaque deposits as well as prevent the formation of new ones. For more information, please visit www.AtheroNova.com.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding the preclinical studies being conducted for the Company by UCLA and the development of applications for AtheroNova's compounds and the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE AtheroNova Inc.